Phenotypic Assessment and the Discovery of Topiramate.

Opportunities and challenges in phenotypic drug discovery: an industry perspective. Nat Rev Drug Discov (2017) 0.75

Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol (2008) 8.51

Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov (2004) 7.57

How were new medicines discovered? Nat Rev Drug Discov (2011) 7.00

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov (2002) 6.13

Opiate receptor: demonstration in nervous tissue. Science (1973) 6.06

Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov (2004) 4.31

Zebrafish behavioral profiling links drugs to biological targets and rest/wake regulation. Science (2010) 3.60

Properties of opiate-receptor binding in rat brain. Proc Natl Acad Sci U S A (1973) 3.34

Target profiling of small molecules by chemical proteomics. Nat Chem Biol (2009) 3.20

Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest (2000) 2.90

An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia (2000) 2.08

SMN2 splice modulators enhance U1-pre-mRNA association and rescue SMA mice. Nat Chem Biol (2015) 1.93

Further properties of stereospecific opiate binding sites in rat brain: on the nature of the sodium effect. J Pharmacol Exp Ther (1975) 1.68

Pathway reporter genes define molecular phenotypes of human cells. BMC Genomics (2015) 1.43

Polypharmacology - foe or friend? J Med Chem (2013) 1.42

Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs (2008) 1.40

Identification of the cardiac beta-adrenergic receptor protein: solubilization and purification by affinity chromatography. Proc Natl Acad Sci U S A (1972) 1.38

Polypharmacology: challenges and opportunities in drug discovery. J Med Chem (2014) 1.35

Single-cell analysis tools for drug discovery and development. Nat Rev Drug Discov (2015) 1.23

Phenotypic screens as a renewed approach for drug discovery. Drug Discov Today (2013) 1.18

Targeting voltage-gated calcium channels in neurological and psychiatric diseases. Nat Rev Drug Discov (2015) 1.02

2009 Edward E Smissman Award. Pharmaceutical "gold" from neurostabilizing agents: topiramate and successor molecules. J Med Chem (2009) 0.93

Identifying compound efficacy targets in phenotypic drug discovery. Drug Discov Today (2015) 0.89

Comparison of sulfamate and sulfamide groups for the inhibition of carbonic anhydrase-II by using topiramate as a structural platform. J Med Chem (2005) 0.87

Back to the future with phenotypic screening. ACS Chem Neurosci (2014) 0.86

Discovering novel neuroactive drugs through high-throughput behavior-based chemical screening in the zebrafish. Front Pharmacol (2014) 0.86

Small molecules and stem cells. Potency and lineage commitment: the new quest for the fountain of youth. J Med Chem (2010) 0.86

Developing predictive assays: the phenotypic screening "rule of 3". Sci Transl Med (2015) 0.85

Phenotypic screening in the 21st century. Front Pharmacol (2014) 0.82

Improving drug discovery with high-content phenotypic screens by systematic selection of reporter cell lines. Nat Biotechnol (2015) 0.82

Human pluripotent stem cells on artificial microenvironments: a high content perspective. Front Pharmacol (2014) 0.81

Mechanisms of action of antiseizure drugs. Handb Clin Neurol (2012) 0.79

Phenotypic screening: the future of antibody discovery. Drug Discov Today (2015) 0.78

Leveraging Large-scale Behavioral Profiling in Zebrafish to Explore Neuroactive Polypharmacology. ACS Chem Biol (2016) 0.76